Spread awareness by sharing and learning more: Post the social media graphic, Listen to past conference sessions, and this webinar. Find these and other opportunities here: Caregiver Health and Wellness section.
What does this FDA approval mean for patients with PNH? Find out how this oral medication, Fabhalta, could replace one of the infusion treatments in this interview with Dr. Bart Scott.
Here is a discussion about recent FDA approval of Tibsovo for Relapsed/Refractory MDS with Dr. Amir Fathi, who is an Associate Professor of Medicine at Harvard Medical School and the Director of the Leukemia Program at Massachusetts General Hospital.
This episode focuses on the US Food and Drug Administration expanded access approval of luspatercept or Reblozyl with Dr. Guillermo Garcia-Manero, Chief of the Section of MDS in the Department of Leukemia at MD Anderson Cancer Center in Houston.
In this webinar, Dr. Thota will discuss what caregivers can expect when their loved one is diagnosed- symptoms and side effects of disease and treatments.
Dr. Lai discusses the latest research presented at the 2023 EHA and ASCO meetings. This is an advanced educational presentation.
In this webinar, Jennie Vagher, certified genetic counselor, discusses hereditary or genetic predisposition to MDS. Jennie is an expert in rare cancer predisposition syndromes.
